Incidence of pediatric inflammatory bowel disease (IBD) in one region of Denmark nearly quadrupled over four decades, ...

Phase 3 results suggest intravenous vedolizumab is effective and safe for clinical remission in pediatric patients with moderate to severe UC.

NEW YORK (Reuters Health) - A study of Northern California children finds that diagnoses of the digestive disease ulcerative colitis increased nearly three-fold between 1996 and 2006 -- for reasons ...

The FDA has approved Remicade from Janssen Biotech to treat moderately to severely active ulcerative colitis in children over age 6 who responded inadequately to conventional therapy, according to an ...

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...

Researchers examined treatment and prognosis for severe-onset ulcerative colitis in children. Children with severe-onset ulcerative colitis may require treatment with biologic agents. Severe-onset ...

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE:JNJ) Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at ...

IBD commonly causes abdominal pain, diarrhea, fatigue, and urgent bowel movements. Crohn's disease and ulcerative colitis often cause symptoms outside of the digestive tract. A high fever, an ...

NYU researchers have found a microbial signature of pediatric Crohn's disease that differs from the makeup of gut bacteria in children with other gastrointestinal conditions, with Crohn's patients ...

OSAKA, Japan & CAMBRIDGE, Mass., February 19, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® ...